...
首页> 外文期刊>Pharmaceutical research >Pharmaceutical Potential of a Novel Chitosan Derivative Schiff Base with Special Reference to Antibacterial, Anti-Biofilm, Antioxidant, Anti-Inflammatory, Hemocompatibility and Cytotoxic Activities
【24h】

Pharmaceutical Potential of a Novel Chitosan Derivative Schiff Base with Special Reference to Antibacterial, Anti-Biofilm, Antioxidant, Anti-Inflammatory, Hemocompatibility and Cytotoxic Activities

机译:新型壳聚糖衍生物Schiff基地的药物潜力,特别参考抗菌,抗生物膜,抗氧化剂,抗炎,血液相位性和细胞毒性活性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PurposeChitosan and its derivatives possess several unique properties relevant in the field of pharmaceutics and medicinal chemistry. This study aimed to evaluate the pharmaceutical performance of an innovative chitosan derivative, methyl acrylate chitosan bearing p-nitrobenzaldehyde (MA*CS*pNBA) Schiff base.MethodsThe antibacterial activity of MA*CS*pNBA was tested against multi-drug resistant (MDR) Gram-negative and Gram-positive bacteria using agar-well diffusion method. Anti-biofilm formation was analyzed using a microtitre plate. Antioxidant assays were performed to assess the scavenging activity of MA*CS*pNBA using DPPH, hydrogen peroxide, superoxide together with its reducing power activity. Anti-inflammatory activity was evaluated by albumin denaturation, membrane stabilization, and proteinase inhibition methods. MA*CS*pNBA was tested for its hemolytic efficiency on human erythrocytes. Cytotoxicity of MA*CS*pNBA was evaluated by MTT assay.ResultsMA*CS*pNBA showed a significant performance as an antibacterial candidate against MDR bacteria, anti-biofilm, antioxidant and anti-inflammatory biomaterial, evidencing hemocompatibility and no cytotoxicity. It exhibited a significant negative correlation with biofilm formation by the MDR-PA-09 strain. Biological activities were found to be significantly concentration-dependent.Conclusionsthe newly chitosan derivative MA*CS*pNBA showed to be promising for pharmaceutical applications, expanding the treatment ways toward skin burn infections since it allied excellent antibacterial, anti-biofilm, antioxidant, anti-inflammatory, hemocompatibility and absence of cytotoxic activities.
机译:Purposechitosan及其衍生物具有几种在药剂学和药用化学领域相关的独特性质。本研究旨在评估创新的壳聚糖衍生物的药物性能,丙烯酸甲酯壳聚糖轴承p-硝基苯甲醛(MA * CS * PNBA)Schiff Base.metheSthe MA * CS * PNBA的抗菌活性,对多药物抗性(MDR)进行了测试使用琼脂孔扩散法的革兰阴性和革兰氏阳性细菌。使用微量滴定板分析抗生物膜形成。进行抗氧化试验以评估使用DPPH,过氧化氢,超氧化物的MA * CS * PNBA的清除活性及其降低功率活性。通过白蛋白变性,膜稳定和蛋白酶抑制方法评估抗炎活性。对人红细胞的溶血效率进行了测试MA * CS * PNBA。 MA * CS * PNBA的细胞毒性通过MTT assay评估.Resultsma * CS * PNBA表现出显着的性能,作为针对MDR细菌,抗生物膜,抗氧化剂和抗炎生物材料,证明血液相位性和无细胞毒性的抗菌候选性的显着性能。它表现出与MDR-PA-09菌株的生物膜形成显着的负相关性。发现生物活性依赖性依赖性浓度。新壳聚糖衍生物MA * CS * PNBA表现为药物应用的前途,扩大了皮肤烧伤感染的治疗方式,因为它依赖于优异的抗菌,抗生物膜,抗氧化剂,抗氧化剂,抗氧化剂,抗氧化剂炎症,血液相位力与细胞毒性活动的缺失。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号